Background Systemic inflammatory response syndrome is a fatal disease because of multiple organ failure. Acute kidney injury is a serious complication of systemic inflammatory response syndrome and its genesis is still unclear posing a difficulty for an effective treatment. Aldose reductase (AR) inhibitor is recently found to suppress lipopolysaccharide (LPS)-induced cardiac failure and its lethality. We studied the effects of AR inhibitor on LPS-induced acute kidney injury and its mechanism. Methods Mice were injected with LPS and the effects of AR inhibitor (Fidarestat 32 mg/kg) before or after LPS injection were examined for the mortality, severity of renal failure and kidney pathology. Serum concentrations of cytokines (interleukin-1β, interleukin-6, monocyte chemotactic protein-1 and tumor necrosis factor-α) and their mRNA expressions in the lung, liver, spleen and kidney were measured. We also evaluated polyol metabolites in the kidney. Results Mortality rate within 72 hours was significantly less in LPS-injected mice treated with AR inhibitor both before (29%) and after LPS injection (40%) than untreated mice (90%). LPS-injected mice showed marked increases in blood urea nitrogen, creatinine and cytokines, and AR inhibitor treatment suppressed the changes. LPS-induced acute kidney injury was associated with vacuolar degeneration and apoptosis of renal tubular cells as well as infiltration of neutrophils and macrophages. With improvement of such pathological findings, AR inhibitor treatment suppressed the elevation of cytokine mRNA levels in multiple organs and renal sorbitol accumulation. Conclusion AR inhibitor treatment ameliorated LPS-induced acute kidney injury, resulting in the lowered mortality.
References
[1]
Riedmann NC, Guo RF, Ward PA (2003) The enigma of sepsis. J Clin Invest 112: 460–467.
[2]
Schrier RW, Wang W (2004) Acute renal failure and sepsis. N Engl J Med 351: 159–169.
[3]
Rangel-Fausto MS, Pittet D, Costigan M, Hwang T, Davis CS, et al. (1995) The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 273: 117–123.
[4]
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 2303–1310.
[5]
Remick DG, Newcomb DE, Bolgos GL, Call DR (2000) Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13: 110–116.
[6]
Hollenberg SM, Broussard M, Osman J, Parrillo JE (2000) Increased microvascular reactivity and improved mortality in septic mice lacking inducible nitric oxide synthase. Circ Res 86: 774–778.
[7]
Schwartz D, Mendonca M, Schwartz I, Xia Y, Satriano J, et al. (1997) Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest 100: 439–448.
[8]
Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, et al. (2001) Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 59: 2243–2249.
[9]
Yabe-Nishimura C (1998) Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 50: 21–33.
[10]
Obrosova IG, Pacher P, Szabo C, Zsengeller Z, Hirooka H, et al. (2005) Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly (ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 54: 234–242.
[11]
Chung SS, Chung SK (2005) Aldose reductase in diabetic microvascular complications. Curr Drug Targets 6: 475–486.
[12]
Ramasamy R, Trueblood N, Schaefer S (1998) Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol 275: H195–203.
[13]
Hwang YC, Shaw S, Kaneko M, Redd H, Marrero MB, et al. (2005) Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial injury. FASEB J 19: 795–797.
[14]
Cheung AK, Lo AC, So KF, Chung SS, Chung SK (2007) Gene deletion and pharmacological inhibition of aldose reductase protect against retinal ischemic injury. Exp Eye Res 85: 608–616.
[15]
Iwata K, Matsuno K, Nishinaka T, Persson C, Yabe-Nishimura C (2006) Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J Pharmacol Sci 102: 37–46.
[16]
Ramasamy R, Oates PJ, Schaefer S (1997) Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 46: 292–300.
[17]
Yagihashi S, Mizukami H, Sugimoto K (2011) Mechanism of diabetic neuropathy: Where are we now and where to go? J Diabetes Invest 2: 18–32.
[18]
Yagihashi S, Mizukami H, Ogasawara S, Yamagishi S, Nukada H, et al. (2010) The role of the polyol pathway in acute kidney injury caused by hindlimb ischaemia in mice. J Pathol 220: 530–541.
[19]
Ramana KV, Willis MS, White MD, Horton JW, DiMaio JM, et al. (2006) Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation 114: 1838–1846.
Kinsey GR, Li L, Okusa MD (2008) Inflammation in acute kidney injury. Nephron Exp Nephrol 109: e102–e107.
[22]
Ramana KV, Reddy AB, Tammali R, Srivastava SK (2007) Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages. Free Radic Biol Med 42: 1290–1302.
[23]
Reddy AB, Srivastava SK, Ramana KV (2009) Anti-inflammatory effect of aldose reductase inhibition in murine polymicrobial sepsis. Cytokine 48: 170–176.
[24]
Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, et al. (1996) Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 97: 1056–1063.
[25]
Oh DJ, Dursun Beta, He Z, Lu L, Hoke TS, et al. (2008) Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol 294: F264–F271.
Ravindranath TM, Mong PY, Ananthakrishnan R, Li Q, Quadri N, et al. (2009) Novel role for aldose reductase in mediating acute inflammatory responses in the lung. J Immunol 183: 8128–8137.
[28]
Kaneko K, Yonemitsu Y, Fujii T, Onimaru M, Jin CH, et al. (2006) A free radical scavenger but not FGF-2-mediated angiogenic therapy rescues myonephropathic metabolic syndrome in severe hindlimb ischemia. Am J Physiol Heart Circ Physiol 290: H1488–1492.
[29]
Benedict CR, Rose JA (1992) Arterial norepinephrine changes in patients with septic shock. Circ Shock 38: 165–172.
[30]
Cumming AD, Driedger AA, McDonald JW, Lindsay RM, Solez K, et al. (1988) Vasoactive hormones in the renal response to systemic sepsis. Am J Kidney Dis 11: 23–32.
[31]
Schor N (2002) Acute renal failure and the sepsis syndrome. Kidney Int 61: 764–776.
[32]
Li L, Huang L, Sung SS, Lobo PI, Brown MG, et al. (2007) NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury. J Immunol 178: 5899–5911.
[33]
Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, et al. (2003) Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Therap 304: 1093–1102.
[34]
Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, et al. (2005) Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 115: 2894–2903.
[35]
Thurman JM, Ljubanovic D, Royer PA, Kraus DM, Molina H, et al. (2006) Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 116: 357–368.
[36]
Shigeoka AA, Holscher TD, King AJ, Hall FW, Kiosses WB, et al. (2007) TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. J Immunol 178: 6252–6258.
[37]
Hwang YC, Kaneko M, Bakr S, Liao H, Lu Y, et al. (2004) Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 18: 1192–1199.
[38]
Lo AC, Cheung AK, Hung VK, Yeung CM, He QY, et al. (2007) Deletion of aldose reductase leads to protection against cerebral ischemic injury. J Cereb Blood Flow Metab 27: 1496–1509.
[39]
Iwata T, Sato S, Jimenez J, McGowan M, Moroni M, et al. (1999) Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha. J Biol Chem 274: 7993–8001.
[40]
Nadkarni V, Gabbay KH, Bohren KM, Sheikh-Hamad D (1999) Osmotic response element enhancer activity. Regulation through p38 kinase and mitogen-activated extracellular signal-regulated kinase kinase. J Biol Chem 274: 20185–20190.
[41]
Kang ES, Woo IS, Kim HJ, Eun SY, Paek KS, et al. (2007) Up-regulation of aldose reductase expression mediated by phosphatidylinositol 3-kinase/Akt and Nrf2 is involved in the protective effect of curcumin against oxidative damage. Free Radic Biol Med 43: 535–545.
